Related references
Note: Only part of the references are listed.Synthesis and Structure-Activity Relationships of 4-Morpholino-7,8-Dihydro-5H-Thiopyrano[4,3-d]pyrimidine Derivatives Bearing Pyrazoline Scaffold
Qinqin Wang et al.
MOLECULES (2017)
Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents
Wei Peng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth
Michele C. Smith et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα, inhibitors
Wufu Zhu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
Debashis Sarker et al.
CLINICAL CANCER RESEARCH (2015)
Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014
Hai-zhong Huo et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment
Xiaoqing Lv et al.
EXPERT OPINION ON DRUG DISCOVERY (2013)
Design, Synthesis and Anticancer Activity of 4-Morpholinothieno[3,2-d]pyrimidine Derivatives Bearing Arylmethylene Hydrazine Moiety
Wufu Zhu et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2012)
Design, synthesis and 3D-QSAR analysis of novel 2-hydrazinyl-4-morpholinothieno[3,2-d]pyrimidine derivatives as potential antitumor agents
Wufu Zhu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2012)
Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer
Daniel P. Sutherlin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor
Timothy P. Heffron et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Lead Optimization of N-3-Substituted 7-Morpholinotriazolopyrimidines as Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of PKI-402
Christoph M. Dehnhardt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Targeting phosphoinositide 3-kinase - Moving towards therapy
Romina Marone et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2008)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)
Share Paper
